Carlo Putzu

724 total citations
22 papers, 301 citations indexed

About

Carlo Putzu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Carlo Putzu has authored 22 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Carlo Putzu's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Carlo Putzu is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Carlo Putzu collaborates with scholars based in Italy, Argentina and Switzerland. Carlo Putzu's co-authors include Stefania Canova, Panagiotis Paliogiannis, Francesca Colonese, Diego Cortinovis, Ciriaco Carru, Angelo Zinellu, Filippo de Braud, Carlo Spreafico, Paolo G. Casali and Petri Bono and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and The Annals of Thoracic Surgery.

In The Last Decade

Carlo Putzu

20 papers receiving 299 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carlo Putzu Italy	9	170	151	65	41	37	22	301
Mónica Enguita‐Germán Spain	10	106 0.6×	162 1.1×	90 1.4×	112 2.7×	29 0.8×	21	358
Elise F. Nassif United States	9	159 0.9×	192 1.3×	80 1.2×	38 0.9×	34 0.9×	37	305
İlhan Hacıbekiroğlu Türkiye	9	148 0.9×	118 0.8×	60 0.9×	55 1.3×	42 1.1×	48	260
Marta Peri Italy	8	180 1.1×	73 0.5×	55 0.8×	43 1.0×	73 2.0×	19	289
Bok Ai Choo Singapore	12	98 0.6×	144 1.0×	55 0.8×	160 3.9×	32 0.9×	29	364
Atsushi Takise Japan	12	232 1.4×	375 2.5×	92 1.4×	77 1.9×	52 1.4×	45	503
Ken Kato Japan	12	187 1.1×	160 1.1×	52 0.8×	133 3.2×	37 1.0×	42	341
Carla Rameri Alexandre Silva de Azevedo Brazil	9	195 1.1×	166 1.1×	15 0.2×	76 1.9×	14 0.4×	17	348
S.‐F. Huang Taiwan	7	119 0.7×	146 1.0×	64 1.0×	53 1.3×	32 0.9×	10	310
Hirohiko Kamiyama Japan	9	185 1.1×	74 0.5×	58 0.9×	126 3.1×	59 1.6×	57	311

Countries citing papers authored by Carlo Putzu

Since Specialization

Citations

This map shows the geographic impact of Carlo Putzu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlo Putzu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlo Putzu more than expected).

Fields of papers citing papers by Carlo Putzu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlo Putzu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlo Putzu. The network helps show where Carlo Putzu may publish in the future.

Co-authorship network of co-authors of Carlo Putzu

This figure shows the co-authorship network connecting the top 25 collaborators of Carlo Putzu. A scholar is included among the top collaborators of Carlo Putzu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlo Putzu. Carlo Putzu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Colombino, Maria, Grazia Palomba, Milena Casula, et al.. (2025). KRAS mutations in non-small cell lung cancer: Translational aspects, current therapies and challenges for future research. Critical Reviews in Oncology/Hematology. 215. 104925–104925.

Putzu, Carlo, Giovanni Maria Fadda, Claudio Sini, et al.. (2024). Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy. Current Oncology. 31(9). 4955–4967. 4 indexed citations

Vito, Andrea De, Paola Bagella, Vito Fiore, et al.. (2023). HIV Infection Indicator Disease-Based Active Case Finding in a University Hospital: Results from the SHOT Project. Infectious Disease Reports. 15(1). 94–101. 3 indexed citations

Putzu, Carlo, Stefania Canova, Panagiotis Paliogiannis, et al.. (2023). Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?. Cancers. 15(3). 689–689. 20 indexed citations

Floris, Matteo, Daria Sanna, Paolo Castiglia, et al.. (2020). MTHFR, XRCC1 and OGG1 genetic polymorphisms in breast cancer: a case-control study in a population from North Sardinia. BMC Cancer. 20(1). 234–234. 18 indexed citations

Perrone, Franco, Michelino De Laurentiis, Sabino De Placido, et al.. (2018). The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid. Annals of Oncology. 29. viii704–viii704. 8 indexed citations

Putzu, Carlo, Diego Cortinovis, Francesca Colonese, et al.. (2018). Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab. Cancer Immunology Immunotherapy. 67(9). 1349–1353. 61 indexed citations

Fois, Alessandro Giuseppe, Paola Crivelli, Carlo Putzu, et al.. (2017). Bronchial mucoepidermoid carcinoma. International Journal of Surgery Case Reports. 31(C). 159–162. 4 indexed citations

Vrdoljak, Eduard, Norbert Marschner, Christoph Zielinski, et al.. (2016). Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Annals of Oncology. 27(11). 2046–2052. 26 indexed citations

10.

Comella, Pasquale, B. Massidda, D. Natale, et al.. (2011). Efficacy and Tolerability of Biweekly Bevacizumab, Irinotecan, Folinic Acid and Fluorouracil Intravenous Bolus (BIFF Regimen) in Patients With Metastatic Colorectal Cancer: The Southern Italy Cooperative Oncology Group Experience. Clinical Colorectal Cancer. 10(1). 42–47. 3 indexed citations

11.

Comella, Pasquale, Vito Lorusso, Luigi Maiorino, et al.. (2009). Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. Cancer Chemotherapy and Pharmacology. 64(5). 893–899. 13 indexed citations

12.

Comella, Pasquale, Vincenzo Emanuele Chiurì, Giuseppe De Cataldis, et al.. (2009). Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer. Lung Cancer. 68(1). 94–98. 5 indexed citations

13.

Comella, Pasquale, Carlo Putzu, B. Massidda, et al.. (2007). Intra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small cell lung cancer patients. Lung Cancer. 56(2). 263–271. 3 indexed citations

14.

Joensuu, Heikki, Filippo de Braud, Paola Coco, et al.. (2007). Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Annals of Oncology. 19(1). 173–177. 53 indexed citations

15.

Pas, Tommaso Martino De, Filippo de Braud, Gianpiero Catalano, et al.. (2006). Oligometastatic Non–Small Cell Lung Cancer: A Multidisciplinary Approach in the Positron Emission Tomographic Scan Era. The Annals of Thoracic Surgery. 83(1). 231–234. 19 indexed citations

16.

Pas, Tommaso De, Carlo Putzu, Giuseppe Curigliano, et al.. (2006). A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. Lung Cancer. 54(3). 359–364. 5 indexed citations

17.

Curigliano, Giuseppe, Carlo M. Cipolla, C. Sessa, et al.. (2006). What is the role of QTc prolongation assessment in new drugs development phase I oncology trials?. Journal of Clinical Oncology. 24(18_suppl). 2006–2006. 5 indexed citations

18.

Comella, P., Gianfranco Filippelli, B. Massidda, et al.. (2006). Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Annals of Oncology. 18(2). 324–330. 39 indexed citations

19.

Comella, Pasquale, B. Massidda, S. Palmeri, et al.. (2006). Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. Anti-Cancer Drugs. 17(8). 985–992. 3 indexed citations

20.

Fadda, Giovanni Maria, Davide Adriano Santeufemia, Paolo Cossu‐Rocca, et al.. (2006). Small Cell Lung Cancer in a Young Patient with Osteopetrosis. Tumori Journal. 92(6). 563–566.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact